A study analyzing SARS-CoV-2 vaccine efficacy and safety in patients with rheumatic and IMIDs- from Argentina registry SAR-CoVAC
Latest Information Update: 28 Jun 2022
At a glance
- Drugs Ad26.COV2 S (Primary) ; AZD 1222 (Primary) ; Coronavirus vaccine-Wuhan Institute of Biological Products (Primary) ; COVID-19 vaccine-Gamaleya National Research Center of Epidemiology and Microbiology (Primary) ; SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- 28 Jun 2022 New trial record
- 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism